Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 17:18:08 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Ultimovacs Q3 2022 - UV1’s moment of truth is drawing closer

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Ultimovacs Q3 2022 - UV1’s moment of truth is drawing closer

2022-11-11 07:23:00

Redeye comments on Ultimovacs’ Q3 2022 report, as the company’s lead candidate is approaching its proverbial ‘moment of truth’ in the form of INITIUM and NIPU top-line data in H1 2023e. Further, we are encouraged by three-year overall survival data from cohort 1 of UV1-103 and are intrigued by biomarker data from the same trial that the company presented in October.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/